- Home
- ONFO vs ONCT Comparison
ONFO vs ONCT Comparison
Compare ONFO & ONCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONFO
- ONCT
- Stock Information
- Founded
- ONFO 2018
- ONCT N/A
- Country
- ONFO United States
- ONCT United States
- Employees
- ONFO N/A
- ONCT N/A
- Industry
- ONFO Computer Software: Programming Data Processing
- ONCT Biotechnology: Pharmaceutical Preparations
- Sector
- ONFO Technology
- ONCT Health Care
- Exchange
- ONFO Nasdaq
- ONCT Nasdaq
- Market Cap
- ONFO 4.5M
- ONCT 4.3M
- IPO Year
- ONFO 2022
- ONCT N/A
- Fundamental
- Price
- ONFO $1.30
- ONCT $1.13
- Analyst Decision
- ONFO
- ONCT Buy
- Analyst Count
- ONFO 0
- ONCT 3
- Target Price
- ONFO N/A
- ONCT $10.00
- AVG Volume (30 Days)
- ONFO 24.9K
- ONCT 157.5K
- Earning Date
- ONFO 11-15-2024
- ONCT 11-06-2024
- Dividend Yield
- ONFO N/A
- ONCT N/A
- EPS Growth
- ONFO N/A
- ONCT N/A
- EPS
- ONFO N/A
- ONCT N/A
- Revenue
- ONFO $6,590,171.00
- ONCT $2,161,000.00
- Revenue This Year
- ONFO $133.59
- ONCT $113.76
- Revenue Next Year
- ONFO N/A
- ONCT N/A
- P/E Ratio
- ONFO N/A
- ONCT N/A
- Revenue Growth
- ONFO 29.25
- ONCT 227.92
- 52 Week Low
- ONFO $0.39
- ONCT $1.03
- 52 Week High
- ONFO $1.80
- ONCT $13.20
- Technical
- Relative Strength Index (RSI)
- ONFO 58.89
- ONCT 37.09
- Support Level
- ONFO $1.04
- ONCT $1.03
- Resistance Level
- ONFO $1.15
- ONCT $1.30
- Average True Range (ATR)
- ONFO 0.13
- ONCT 0.19
- MACD
- ONFO -0.01
- ONCT -0.01
- Stochastic Oscillator
- ONFO 62.00
- ONCT 13.70
About ONFO Onfolio Holdings Inc.
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place.
About ONCT Oncternal Therapeutics Inc.
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.